SCHEMBL2902357

SCHEMBL2902357

CN1CCCN(C(c2ccc(-c3cccc(F)c3)cc2)c2c[nH]nc2-c2ccco2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.37
PIK3R1 P27986 2/20 0.36
PIK3CA P42336 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
ADRA1A P35348 1/20 0.35
OPRM1 P35372 1/20 0.35
DRD3 P35462 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
USP2 O75604 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909335 0.92 HRH3 (0.43) HRH3PIK3R1PIK3CASMN1; SMN2ALDH1A1
SCHEMBL2902613 0.87 PIK3R1 (0.37) HRH3PIK3R1PIK3CAALDH1A1CYP3A4
SCHEMBL2903067 0.87 OPRD1 (0.37) HRH3PIK3R1PIK3CAHTR1ASLC6A2
SCHEMBL2909115 0.86 PTK2 (0.36) HRH3SMN1; SMN2ALDH1A1CHRM2HTR1A
SCHEMBL2910374 0.85 ALDH1A1 (0.41) PIK3R1PIK3CASMN1; SMN2ALDH1A1USP2
Morpholine SCHEMBL2905731 0.84 OPRD1 (0.35) PIK3R1PIK3CAHTR1ASLC6A2SLC6A4
SCHEMBL2904791 0.82 CYP3A4 (0.42) ALDH1A1USP2CYP3A4LMNAKDM4E
SCHEMBL2907701 0.82 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1USP2CYP3A4CYP2D6
SCHEMBL2908848 0.81 LRRK2 (0.36) PIK3R1PIK3CALMNAMAPT
SCHEMBL2904606 0.81 P2RX3 (0.37) HRH3ALDH1A1CHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A HRH3 111/4885PIK3R1 2479/4885PIK3CA 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.